Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telintra for Chemotherapy Induced Neutropenia in NSCLC
NCT00701870Phase 2Terminated
- Sponsor
- Telik, Inc.
- Start
- Oct 2008
- Primary completion
- Nov 2008
- Modality
- Peptides, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ezatiostat in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Telik, Inc. Primary endpoint: Duration of chemotherapy induced neutropenia at 6 weeks. Started Oct 2008; status: terminated.
02
Drugs
ezatiostat
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT00701870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701870.